MaxCyte Reports Second Quarter 2026 Financial Results
MAXCYTE, INC. (MXCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MaxCyte Reports Second Quarter 2026 Financial Results · Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue · Reiterates Full Year 2026 Guidance · Repurchased a
How this was made
The 30-second read
Why it matters
Q2 results show total revenue down 15% YoY and core revenue down 21% YoY, while SPL program-related revenue rose to $0.8M. The company reiterated full-year revenue guidance of $30M to $32M and expects year-end cash of at least $130.5M (excluding further buyback deployment). The newly signed multi-platform license with Genentech is positioned as unlocking new opportunities and supporting long-term value via SPL royalties and clinical program advancement.
Market read
Traders can update models using the explicit Q2 financials and the reiterated full-year revenue and cash guidance, and reassess the revenue mix impact of SPL growth versus core weakness.
What to watch
Non-GAAP gross margin excludes SPL-related revenue and inventory reserves; traders may want to track whether SPL program-related revenue scales enough to stabilize consolidated margins and cash burn.
MaxCyte reported second-quarter total revenue of $7.3 million, down 15% year over year, reiterated full-year 2026 guidance, and reported approximately $5.5 million of share repurchases to date.
Revenue, core revenue and gross margin declined year over year, while net loss, EBITDA loss and operating expenses improved. The company reiterated full-year guidance and highlighted rising commercial royalty revenue and a new Genentech technology license partnership.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total RevenueGAAP | $7.27M | – | (15%) |
| Total Core RevenueGAAP | $6.50M | – | (21%) |
| SPL Program-related revenueGAAP | $800K | – | – |
| Gross profitGAAP | $5.6M | – | – |
| Gross marginGAAP | 77% gross margin | – | – |
| Adjusted gross marginnon-GAAP | 77% | – | – |
| Operating expensesGAAP | $15.8M | – | – |
| Net lossGAAP | $8.9M | – | – |
| EBITDA lossnon-GAAP | $9.3M | – | – |
| Stock-based compensation expenseother | $1.2M | – | – |
| Total SPL agreementsother | 29 | – | – |
| SPL programs currently in the clinicother | 12 programs | – | – |
| Commercial SPL programsother | one commercial program | – | – |
| Total cash, cash equivalents and investmentsother | $141.9M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| InstrumentsManagement cited execution on instrument placements. | $1.76M | – | (18%) |
| PAs and ConsumablesManagement cited stability in processing assembly sales. | $2.34M | – | (25%) |
| LicensesNot separately disclosed. | $1.82M | – | (30%) |
| Assay ServiceNot separately disclosed. | $245K | – | 380% |
| OtherNot separately disclosed. | $338K | – | 31% |
| MilestonesNot separately disclosed. | $4K | – | 0% |
| RoyaltiesGrowing commercial royalty revenue. | $764K | – | 150% |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Full Year 2026 outlook
- Revenue$30 million to $32 million
- NoteCore revenue of $25 million to $27 million.
- NoteSPL Program-related revenue of approximately $5 million for the year.
- NoteRevenue of approximately $3 million from milestone payments.
- NoteApproximately $2 million from commercial royalties.
- NoteAt least $130.5 million in total cash, cash equivalents and investments, excluding any further capital deployed toward the share repurchase program.
Capital returns
- Repurchased approximately $5.5 million of common stock to date under the Company’s $10 million share repurchase program authorized by the Board.
What drove it
- Management said second-quarter results were driven by execution on instrument placements and stability in processing assembly sales.
- Royalties were $ 764 (in thousands), up 150%, and management cited growing commercial royalty revenue.
- The company announced a strategic, multi-platform technology license partnership with Genentech in July.
- The SPL portfolio included 29 agreements, 12 programs currently in the clinic, and one commercial program as of June 30, 2026.
Concerns
- Total revenue decreased 15% year over year to $ 7,271 (in thousands).
- Total core revenue decreased 21% year over year to $ 6,503 (in thousands).
- Instruments, PAs and Consumables, and Licenses declined 18%, 25%, and 30%, respectively.
- GAAP gross margin was 77% gross margin, compared to 82% gross margin in the second quarter of 2025.
- The company reported a net loss of $8.9 million and an EBITDA loss of $9.3 million.
What to watch
- Execution against full-year revenue guidance of $30 million to $32 million.
- Core revenue delivery within the $25 million to $27 million full-year guidance range.
- SPL Program-related revenue of approximately $5 million, including approximately $3 million from milestone payments and approximately $2 million from commercial royalties.
- Additional progress from the Genentech multi-platform technology license partnership.
- Further capital deployed toward the share repurchase program and year-end total cash, cash equivalents and investments of at least $130.5 million.
Balance sheet and cash flow
- Total cash, cash equivalents and investments were $141.9 million as of June 30, 2026.
- MaxCyte expects to end 2026 with at least $130.5 million in total cash, cash equivalents and investments, excluding any further capital deployed toward the share repurchase program.
Analysis
MaxCyte's second-quarter revenue performance remained pressured. Total revenue was $ 7,271 (in thousands), down 15%, while total core revenue was $ 6,503 (in thousands), down 21%. The decline was broad across the largest reported core revenue sources: Instruments declined 18%, PAs and Consumables declined 25%, and Licenses declined 30%. Assay Service increased 380% and Other increased 31%, but the release did not provide a quantified explanation for those changes.
SPL activity was a relative strength. SPL Program-related revenue was $0.8 million, compared to $0.3 million in the second quarter of 2025. Royalties were $ 764 (in thousands), up 150%, while Milestones were $ 4 (in thousands) and unchanged. The portfolio comprised 29 SPL agreements as of June 30, 2026, including 12 programs currently in the clinic and one commercial program. Management also highlighted its July multi-platform technology license partnership with Genentech.
Margins and losses improved in some respects but remain central to the quarter. Gross profit was $5.6 million, compared to $7.0 million, and GAAP gross margin declined to 77% gross margin from 82% gross margin. Non-GAAP adjusted gross margin was 77%, compared to 83%. Operating expenses fell to $15.8 million from $21.2 million, and net loss narrowed to $8.9 million from $12.4 million. EBITDA loss improved to $9.3 million from $13.1 million, alongside stock-based compensation expense of $1.2 million compared to $3.5 million.
Capital resources were $141.9 million of total cash, cash equivalents and investments as of June 30, 2026. The company had repurchased approximately $5.5 million of common stock to date under its $10 million authorized program. MaxCyte reiterated full-year revenue guidance of $30 million to $32 million, including core revenue of $25 million to $27 million and SPL Program-related revenue of approximately $5 million. It expects to end 2026 with at least $130.5 million in total cash, cash equivalents and investments, excluding any further capital deployed toward the share repurchase program.
The release provides year-over-year comparisons but no prior-quarter financial comparisons, so quarter-over-quarter changes are not reported. The key reported issues are whether instrument placements and processing assembly sales support a return to core revenue growth, whether commercial royalty revenue continues to develop, and whether cost reductions can offset the lower gross-margin profile while the company pursues its reiterated full-year revenue plan.
Management, verbatim
We are pleased with our second quarter results, which were ahead of our expectations, driven by execution on instrument placements and stability in processing assembly sales.
Maher Masoud, President and CEO of MaxCyte
A significant development for MaxCyte was the recent signing of our first multi-platform technology license partnership with large pharma, an enterprise-level agreement with Genentech that we believe will unlock meaningful new opportunities for MaxCyte.
Maher Masoud, President and CEO of MaxCyte
Lastly, our goal has been to return to revenue growth while reducing our net losses.
Maher Masoud, President and CEO of MaxCyte
Not in the filing
stated, not guessed- GAAP operating income or loss
- GAAP diluted EPS
- Non-GAAP diluted EPS
- Operating cash flow
- Free cash flow
- Debt balance
- Dividend information
- Prior-quarter comparisons for reported revenue, margin, expense, loss, EBITDA, stock-based compensation, SPL portfolio, and cash metrics
- Full-year 2026 guidance for gross margin, operating expenses, and tax rate
- Previous-quarter outlook for comparison with reported results
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC Form 8-K (Item 2.02) with MaxCyte’s Q2 2026 results, full-year 2026 guidance, and related disclosures including a share repurchase update and a newly announced Genentech technology license partnership.
Ticker impact
MaxCyte reported Q2 2026 revenue of $7.3M, reiterated 2026 guidance, and disclosed a $5.5M buyback plus a Genentech multi-platform license deal.
Near-term bias upward on guidance confidence and the Genentech partnership narrative, with volatility risk from the reported core revenue decline and gross margin compression.
The article provides concrete financial figures (revenue, gross margin, net loss), explicit full-year revenue ranges, and a newly signed enterprise license partnership with Genentech, all of which are actionable for positioning. However, it does not provide deal economics (upfront/milestones/royalty rates), limiting precision on magnitude.
Market effects
Reinforces demand for cell-engineering enabling platforms and multi-platform licensing models, potentially supporting sentiment toward adjacent cell therapy tooling names.
Limited direct regional read-through; primarily US-listed biotech tooling sentiment.
Genentech partnership signals continued global large-pharma investment in enabling technologies, but deal size details are not provided here.
Counterpoint
The headline partnership may not offset the ongoing core revenue decline and gross margin deterioration, so the market could focus on whether SPL growth can sustainably replace core weakness.
Key entities
- issuerMaxCyte, Inc.
Cell-engineering enabling platform company reporting Q2 2026 results, reiterating 2026 guidance, and announcing a Genentech multi-platform technology license partnership.
- partnerGenentech
Large pharma partner named in a newly signed enterprise-level multi-platform technology license partnership with MaxCyte.
